84. サルコイドーシス
［臨床試験数：143，薬物数：221（DrugBank：79），標的遺伝子数：82，標的パスウェイ数：165］
Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-004148-31-NL (EUCTR) | 26/02/2020 | 15/11/2019 | The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial | The PREDMETH trial: Effectiveness of methotrexate versus prednisone as first-line therapy for pulmonary sarcoidosis – A randomized controlled trial - PREDMETH trial | pulmonary sarcoidosis;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] | Trade Name: Methotrexate Product Name: methotrexate INN or Proposed INN: methotrexate Other descriptive name: METHOTREXATE Trade Name: Prednison Product Name: Prednison INN or Proposed INN: prednisone Other descriptive name: PREDNISONE | Erasmus Medisch Centrum Dept. of Pulmonology | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 132 | Phase 4 | Netherlands | ||
| 2 | NCT03593759 (ClinicalTrials.gov) | January 15, 2019 | 27/6/2018 | Cardiac Sarcoidosis Randomized Trial | Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone;Drug: Methotrexate | Ottawa Heart Institute Research Corporation | Canadian Institutes of Health Research (CIHR) | Recruiting | 18 Years | N/A | All | 194 | Phase 3 | United States;Canada;United Kingdom |
| 3 | NCT03324503 (ClinicalTrials.gov) | December 8, 2017 | 12/10/2017 | A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis | A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis | Sarcoidosis, Pulmonary | Drug: Glucocorticoid (prednisone or prednisolone) | Celgene | NULL | Completed | 18 Years | 65 Years | All | 8 | N/A | United States;Netherlands;United Kingdom |
| 4 | NCT01210677 (ClinicalTrials.gov) | April 2014 | 27/9/2010 | Cardiac Sarcoidosis Response To Steroids Trial | CArdiac Sarcoidosis Response TO steRoids (CASTOR) Trial | Cardiac Sarcoidosis;Sarcoidosis | Drug: Prednisone | Ottawa Heart Institute Research Corporation | NULL | Withdrawn | 18 Years | N/A | Both | 0 | Phase 4 | Canada |
| 5 | NCT02200146 (ClinicalTrials.gov) | March 2009 | 10/7/2014 | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). | Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial. | Pulmonary Sarcoidosis | Drug: Prednisone;Drug: Hydroxychloroquine + Prednisone | University of Milano Bicocca | Agenzia Italiana del Farmaco | Completed | 18 Years | 70 Years | Both | 94 | Phase 3 | Italy |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2008-001340-39-IT (EUCTR) | 30/06/2008 | 13/06/2008 | Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS | Hydroxychloroquine as Steroid-Sparing Agent in pulmonary Sarcoidosis (HySSAS). A multicenter, prospectic, controlled, randomized trial. - HySSAS | Pulmonary Sarcoidosis | Trade Name: PLAQUENIL*25CPR RIV 200MG INN or Proposed INN: Hydroxychloroquine Trade Name: DELTACORTENE*10CPR 25MG INN or Proposed INN: Prednisone | UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Italy | ||||
| 7 | NCT00000596 (ClinicalTrials.gov) | June 1978 | 27/10/1999 | Diffuse Fibrotic Lung Disease | Lung Diseases;Pulmonary Fibrosis;Sarcoidosis | Drug: prednisone;Drug: cyclophosphamide;Drug: dapsone | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Completed | 18 Years | N/A | Both | Phase 2 | NULL |